2025 / 04

Next Paper
DOI: 10.24075/brsmu.2025.040
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Comparison of the efficacy of mRNA vaccines against M. tuberculosis based on linear and circular RNAs

Kirshina AS1, Shepelkova GS2, Khlebnikova AS1, Maslov AA1, Kozlova AV1, Kunyk DA1, Yeremeev VV2, Ivanov RA1, Reshetnikov VV1
About authors

1 Sirius University of Science and Technology, Sirius, Russia

2 Central Tuberculosis Research Institute, Moscow, Russia

Correspondence should be addressed: Vasily V. Reshetnikov
Olimpiysky prospekt, 1, Sochi, 354340, Russia; ur.hepsuitnalat@vv.vokintehser, Vladimir V. Yeremeev, Yauzskaya alleya, 2, Moscow, 107564; Russia; ur.liam@65veemerey

About paper

Funding: the study was conducted within the framework of the State Assignment of the Central Tuberculosis Research Institute, R&D project: FURE-2025-0018.

Acknowledgements: the authors express their gratitude to O.V. Zaborova, staff member of the Sirius University of Science and Technology, for formulation of mRNA into lipid nanoparticles and E.I. Chebanyuk, staff member of the biotechnology laboratory of the Central Tuberculosis Research Institute, for assistance in animal handling and setting the experiments involving lineal mice.

Author contribution: Kirshina AS, Khlebnikova AS — mRNA vaccine preparation, planning the experiment, manuscript writing; Kozlova AV, Kunyk DA, Maslov AA — mRNA vaccine preparation; Shepelkova GS — experimental procedure, data analysis; Yeremeev VV, Ivanov RA — planning the experiment, manuscript editing; Reshetnikov VV — mRNA vaccine preparation, planning the experiment, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Central Tuberculosis Research Institute (protocol No. 3/2 dated 11 May 2022) and conducted in accordance with the Order of the Ministry of Health No. 755 and the Guidelines issued by the Office of Laboratory Animal Welfare (А5502-01).

Received: 2025-07-22 Accepted: 2025-08-17 Published online: 2025-08-26
|
  1. Global Tuberculosis Report 2024. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024 (access date: 19.05.2025).
  2. Kazakova A, Zhelnov P, Sidorov R, Rogova A, Vasileva O, Ivanov R, et al. DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies. Frontiers in Immunology. 2024; 15: 1457327.
  3. Working Group for New TB Vaccines. Available from: https://newtbvaccines.org/ (дата обращения: 12.07.2025).
  4. Baden LR, El Sahly H.M, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021; 384 (5): 403–16.
  5. Khlebnikova A, Kirshina A, Zakharova N, Ivanov R, Reshetnikov V. Current Progress in the Development of mRNA Vaccines Against Bacterial Infections. International Journal of Molecular Sciences. 2024; 25 (23): 13139.
  6. Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnology Advances. 2020; 40: 107534.
  7. Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. Journal of Controlled Release. 2022; 348: 84–94.
  8. Hwang HJ, Kim YK. Molecular mechanisms of circular RNA translation. Experimental & molecular medicine. 2024; 56 (6): 1272–80.
  9. Margvelani G, Maquera KAA, Welden JR, Rodgers DW, Stamm S. Translation of circular RNAs. Nucleic acids research. 2025; 53 (1): gkae1167.
  10. Zhou J, Ye T, Yang Y, Li E, Zhang K, Wang Y, et al. Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice. Molecular Therapy. 2024; 32 (6): 1779–89.
  11. Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022; 185 (10): 1728–44.
  12. Radaeva TV, Nikonenko BV, Mischenko VV, Averbakh MM, Apt AS. Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice. Tuberculosis. 2005; 85 (1–2): 65–72.
  13. Reshetnikov V, et al. The Candidate Anti-Tuberculosis MRNA Vaccine Immunogenicity and Reactogenicity Dependency on the Animal’s Sex and the Vaccine Dose. Bull. Russ. State Med. Univ. 2024; 5: 25–31.
  14. Kozlova A, Pateev I, Shepelkova G, Vasileva O, Zakharova N, Yeremeev V, et al. A Cap-Optimized MRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against Mycobacterium tuberculosis. Vaccines. 2024; 12 (11): 1267.
  15. Reshetnikov V, Terenin I, Shepelkova G, Yeremeev V, Kolmykov S, Nagornykh M, et al. Untranslated region sequences and the efficacy of mRNA vaccines against tuberculosis. International Journal of Molecular Sciences. 2024; 25 (2): 888.
  16. Avdienko VG, Babayan SS, Bocharova IV. Characteristics and application of monoclonal antibodies to Mycobacterium kansasii. CTRI Bulletin. 2024; 8 (4): 51–60.
  17. Nikonenko BV, Apt AS, Mezhlumova MB, Avdienko VG, Yeremeev VV, Moroz AM. Influence of the mouse Bcg Tbc-1 and xid genes on resistance and immune responses to tuberculosis infection and efficacy of bacille Calmette–Guérin (BCG) vaccination. Clinical and Experimental Immunology. 2003; 104 (1) 37–43.
  18. Yang Y, Wang Z. IRES-mediated cap-independent translation, a path leading to hidden proteome. Journal of molecular cell biology. 2019; 11 (10): 911–9.
  19. Lai R, Ogunsola AF, Rakib T, Behar SM. Key advances in vaccine development for tuberculosis—success and challenges. NPJ vaccines. 2023; 8 (1): 158.
  20. Rijnink WF, Ottenhoff TH, Joosten SA. B-cells and antibodies as contributors to effector immune responses in tuberculosis. Frontiers in immunology. 2021; 12: 640168.
  21. Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021; 196: 85–103.
  22. Chen YG, Kim MV, Chen X, Batista PJ, Aoyama S, Wilusz JE. Sensing self and foreign circular RNAs by intron identity. Molecular cell. 2017; 67 (2): 228–38.
  23. Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nature Reviews Immunology. 2020; 20 (9): 537–51.
  24. Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001; 14 (4): 461–70.
  25. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nature Reviews Immunology. 2015; 15 (4): 231–42.
  26. Cole St, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998; 396 (6707): 190.
  27. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. The Lancet infectious diseases. 2007; 7 (5): 328–37.